Evidence map›Paper›PMID 23290417›Full record

ArticleMolecular oncology2013

Targeting HER2-positive cancer cells with receptor-redirected anthrax protective antigen.

Andrew J McCluskey, Andrew J Olive, Michael N Starnbach, R John Collier

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 67 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Protective antigen-mediated delivery of an anti-CRISPR protein for precision genome editing.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Bacterial Toxin and Effector Regulation of Intestinal Immune Signaling.Frontiers in cell and developmental biology · 2022
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Andrew J McCluskeyDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA.
Andrew J Olive
Michael N Starnbach
R John Collier
Harvard University · US

Funding

Treatments for Nipah Virus InfectionU54AI057159 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI KASPER, DENNIS L. · 2003 to 2013
$113.7M
Cytotoxic T Cell Mediated Immunity to ChlamydiaR01AI039558 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI STARNBACH, MICHAEL N · 2001 to 2025
$15.6M
MOLECULAR MECHANISMS OF BACTERIAL PATHOGENESISR37AI022021 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI COLLIER, ROBERT JOHN · 1988 to 2007
$6.1M
MOLECULAR MECHANISMS OF BACTERIAL PATHOGENESISR01AI022021 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI COLLIER, ROBERT JOHN · 1985 to 2012
$3.9M
Genetics of Host Resistance to Chlamydia trachomatisR01AI062827 · NIAID · HARVARD MEDICAL SCHOOL · PI STARNBACH, MICHAEL N · 2006 to 2014
$3.8M
NIAID NIH HHS AI022021NIAID NIH HHS AI057159NIAID NIH HHS AI062827NIAID NIH HHS R01 AI022021NIAID NIH HHS R01 AI039558NIAID NIH HHS R01 AI062827NIAID NIH HHS R37 AI022021NIAID NIH HHS U54 AI057159
6 · The paper itself

Abstract

Targeted therapeutics have emerged in recent years as an attractive approach to treating various types of cancer. One approach is to modify a cytocidal protein toxin to direct its action to a specific population of cancer cells. We created a targeted toxin in which the receptor-binding and pore-forming moiety of anthrax toxin, termed Protective Antigen (PA), was modified to redirect its receptor specificity to HER2, a marker expressed at the surface of a significant fraction of breast and ovarian tumors. The resulting fusion protein (mPA-ZHER2) delivered cytocidal effectors specifically into HER2-positive tumor cells, including a trastuzumab-resistant line, causing death of the cells. No off-target killing of HER2-negative cells was observed, either with homogeneous populations or with mixtures of HER2-positive and HER2-negative cells. A mixture of mPA variants targeting different receptors mediated killing of cells bearing either receptor, without affecting cells devoid of these receptors. Anthrax toxin may serve as an effective platform for developing therapeutics to ablate cells bearing HER2 or other tumor-specific cell-surface markers.

Indexed as

Antibodies, Monoclonal, HumanizedAntigens, BacterialBacterial ToxinsCell DeathCell Line, TumorCell SurvivalDrug Delivery SystemsDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesErbB ReceptorsHumansNeoplasmsRecombinant Fusion ProteinsTrastuzumabaffibody (ZHER2-342)2anthrax toxinAntibodies, Monoclonal, HumanizedAntigens, BacterialBacterial ToxinsErb-b2 Receptor Tyrosine KinasesErbB ReceptorsRecombinant Fusion ProteinsTrastuzumab

Identifiers

PMID23290417
PMCPMC3621010
OpenAlexW1995139161

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.